Français
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Page 1 de 65 résultats
Observational Study of Iris Tumors
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
NaliCap (Irinotecan Liposome (Nal-IRI)/Capecitabine) vs. NAPOLI (Nal-IRI/5-FU/LV) ) in Advanced Pancreatic Cancer
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
- At the time of initial diagnosis of pancreatic cancer, resectable pancreatic cancer is around 20%, locally-advanced pancreatic cancer is around 25-30%, and the remaining is metastatic pancreatic cancer.
- In metastatic pancreatic cancer, Gemcitabine/Abraxane or FOLFIRINOX
First Line Metastatic Pancreatic Cancer : 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
Pancreatic cancer (PC) is the seventh cause from cancer and the fifth cause from cancer-related death in Europe. Nearly as many deaths occur from PC than the number of new cases diagnosed each year, reflecting the poor prognosis typically associated with this disease. PC is insidious in onset and is
TAS102 in Combination With NAL-IRI in Advanced GI Cancers
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
PRIMARY OBJECTIVES:
I. Determine the recommended phase II dose for the combination of TAS-102 and nanoliposomal irinotecan (nanoliposomal [nal]-IRI). (Phase I)
II. Evaluate the activity of the combination of TAS102 and nal-IRI in previously treated patients with metastatic colorectal cancer and
Second Line Treatment With Nal-IRI and S1 in Pancreatic Cancer
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
The 5-year survival of patients with pancreatic cancer is less than 5%. Despite improvements over the past years with the introduction of FOLFIRINOX (5-fluorouracil, irinotecan, oxaliplatin and leucovorin) and gemcitabine and nab-paclitaxel, the vast majority will have disease recurrence or
Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS)
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
This study has two cohorts. In Cohort A, patients who met the inclusion criteria(ER，PR<10%, T≤2cm or ER,PR ≥10% 1cm＜T≤2cm）would be given capecitabine for 6 cycles with standard trastuzumab for 1 year, in which HR+ patients would be given endocrine therapy for 5 years. In Cohort B, patients who met
IRIS Followed by mFOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
A multicenter randomized open-label controlled phase III study is conducted in patients with inoperable advanced or metastatic colorectal cancer who receive no previous chemotherapy. Usefulness of IRIS and mFOLFOX6 regimens as the 1st-line therapy for colorectal cancer is evaluated in PFS, MST,
Trial of FOLF(HA)Iri With Cetuximab in mCRC
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
Trial of FOLF(HA)Iri Versus FOLFIRI in mCRC
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
Nal-IRI(Nanoliposomal Irinotecan) Plus 5-FU/LV in Metastatic Biliary Tract Cancer
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
This study is a multicenter, open-label, randomized, phase II study comparing the efficacy and safety between fluorouracil/folinic acid plus liposomal irinotecan and fluoruracil/folinic acid monotherapy in patients with metastatic biliary tract cancer which progressed on 1st line
Vactosertib With Nal-IRI/FL in Metastatic Pancreatic Ductal Adenocarcinoma.
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
- Number of patients : Total 24 patients (6-12 patients in phase 1 part and 12 patients in expansion cohort )
- Treatment :
- Vactosertib* 100-300 mg bid for 5 days
- Liposomal Irinotecan (Onivyde) 70mg/m2 on D1
- LV 200mg/m2 IV bolus on D1
- 5-FU 2400mg/m2 CIV over 46 hours on D1
- Vactosertib will
Phase II Study of Oral S-1 Plus Irinotecan (IRIS) in Patients With Advanced Colorectal Cancer
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
A multicenter Open-label, single-arm, phase II clinical trial is conducted on patients with histological stage IV colorectal cancer given irinotecan plus S-1. The usefulness of this regimens as 1st line therapy for colorectal cancer was evaluated by the disease-free survival rate (DFR), overall
Cap/Iri Plus Cetuximab Compared to Cap/ox Plus Cetuximab in Patients With Metastatic Colorectal Cancer.
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
Part 1: Patients will be enrolled to determine the maximum tolerated dose, safety and tolerability of MM-151 + nal-IRI + 5-FU + LV in patients with mCRC that are RAS/RAF wild-type.
Part 2: Patients will be enrolled at the maximum tolerated dose of MM-151 in combination with nal-IRI + 5-FU + LV to
Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
Primary Objectives
- to determine the maximum tolerated dose (MTD) of nal-IRI (ONIVYDE®) in combination with TAS-102 (LONSURF®)
- to evaluate the toxicity profile of the combination therapy Secondary Objectives
- to evaluate the preliminary efficacy of the combination therapy of nal-IRI (ONIVYDE®)
La base de données d'herbes médicinales la plus complète soutenue par la science
- Fonctionne en 55 langues
- Cures à base de plantes soutenues par la science
- Reconnaissance des herbes par image
- Carte GPS interactive - étiquetez les herbes sur place (à venir)
- Lisez les publications scientifiques liées à votre recherche
- Rechercher les herbes médicinales par leurs effets
- Organisez vos intérêts et restez à jour avec les nouvelles recherches, essais cliniques et brevets
Tapez un symptôme ou une maladie et lisez des informations sur les herbes qui pourraient aider, tapez une herbe et voyez les maladies et symptômes contre lesquels elle est utilisée.
* Toutes les informations sont basées sur des recherches scientifiques publiées
